- Home
- TEI vs CDXS Comparison
TEI vs CDXS Comparison
Compare TEI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- CDXS
- Stock Information
- Founded
- TEI 1993
- CDXS 2002
- Country
- TEI United States
- CDXS United States
- Employees
- TEI N/A
- CDXS N/A
- Industry
- TEI Finance Companies
- CDXS Major Chemicals
- Sector
- TEI Finance
- CDXS Industrials
- Exchange
- TEI Nasdaq
- CDXS Nasdaq
- Market Cap
- TEI 282.9M
- CDXS 254.3M
- IPO Year
- TEI N/A
- CDXS 2010
- Fundamental
- Price
- TEI $6.37
- CDXS $2.49
- Analyst Decision
- TEI
- CDXS Buy
- Analyst Count
- TEI 0
- CDXS 2
- Target Price
- TEI N/A
- CDXS $11.00
- AVG Volume (30 Days)
- TEI 142.4K
- CDXS 945.1K
- Earning Date
- TEI 01-01-0001
- CDXS 10-30-2025
- Dividend Yield
- TEI 10.51%
- CDXS N/A
- EPS Growth
- TEI N/A
- CDXS N/A
- EPS
- TEI N/A
- CDXS N/A
- Revenue
- TEI N/A
- CDXS $57,164,000.00
- Revenue This Year
- TEI N/A
- CDXS $12.88
- Revenue Next Year
- TEI N/A
- CDXS $21.64
- P/E Ratio
- TEI N/A
- CDXS N/A
- Revenue Growth
- TEI N/A
- CDXS N/A
- 52 Week Low
- TEI $4.35
- CDXS $1.90
- 52 Week High
- TEI $5.39
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- TEI 62.41
- CDXS 44.57
- Support Level
- TEI $6.12
- CDXS $2.34
- Resistance Level
- TEI $6.53
- CDXS $2.54
- Average True Range (ATR)
- TEI 0.09
- CDXS 0.12
- MACD
- TEI 0.02
- CDXS 0.00
- Stochastic Oscillator
- TEI 64.57
- CDXS 42.55
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.